Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

G.P. van der Wijst, Monique; E. Vazquez, Sara; C. Hartoularos, George; Bastard, Paul; Grant, Tianna; Bueno, Raymund; Lee, David; R. Greenland, John; Sun, Yang; K. Perez, Richard; Ogorodnikov, Anton; Ward, Alyssa; A Mann, Sabrina; L. Lynch, Kara; Yun, Cassandra; V. Havlir, Diane; Chamie, Gabriel; Marquez, Carina; Greenhouse, Bryan; S. Lionakis, Michail; J. Norris, Philip; J. Dumont, Larry; Kelly, Kathleen; Zhang, Peng; Zhang, Qian; Gervais, Adrian; Le Voyer, Tom; Whatley, Alexander; Si, Yichen; Byrne, Ashley; J. Combes, Alexis; A. Rao, Arjun; S. Song, Yun; K. Fragiadakis, Gabriela; N. Kangelaris, Kirsten; S. Calfee, Carolyn; J. Erle, David; M. Hendrickson, Carolyn; F. Krummel, Matthew; G. Woodruff, Prescott; Langelier, Charles; Casanova, Jean‐Laurent; L. DeRisi, Joseph; S. Anderson, Mark; Ye, Chun

doi:10.1126/scitranslmed.abh2624

Public

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

Published in Science Translational Medicine • Aug 24, 2021

Authors:

Monique G.P. van der Wijst

Sara E. Vazquez

George C. Hartoularos

Abstract

Neutralizing autoantibodies against type I interferons (IFNs) have been found in some patients with critical coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the prevalence of these antibodies, their longitudinal dynami...

Subject

Autoantibody

Immunology

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!